A Top-Down Design Approach for Generating a Peptide PROTAC Drug Targeting Androgen Receptor for Androgenetic Alopecia Therapy
Authors:
- 5 June 2024
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (12) , 10336-10349
Abstract
While large-scale artificial intelligence (AI) models for protein structure prediction and design are advancing rapidly, the translation of deep learning models for practical macromolecular drug development remains limited. This investigation aims to bridge this gap by combining cutting-edge methodologies to create a novel peptide-based PROTAC drug development paradigm. Using ProteinMPNN and RFdiffusion, we identified binding peptides for androgen receptor (AR) and Von Hippel-Lindau (VHL), followed by computational modeling with Alphafold2-multimer and ZDOCK to predict spatial interrelationships. Experimental validation confirmed the designed peptide's binding ability to AR and VHL. Transdermal microneedle patching technology was seamlessly integrated for the peptide PROTAC drug delivery in androgenic alopecia treatment. In summary, our approach provides a generic method for generating peptide PROTACs and offers a practical application for designing potential therapeutic drugs for androgenetic alopecia. This showcases the potential of interdisciplinary approaches in advancing drug development and personalized medicine.Keywords
Funding Information
- National Key Research and Development Program of China (2023YFC3404100)
- National Natural Science Foundation of China (81925028, 82002717)
- Natural Science Foundation of Shaanxi Province (2021ZDLSF02-15)
This publication has 40 references indexed in Scilit:
- Bifunctional Peptide Nanofibrils for Targeted Protein DegradationAngewandte Chemie International Edition, 2023
- A GPX4 non-enzymatic domain and MDM2 targeting peptide PROTAC for acute lymphoid leukemia therapy through ferroptosis inductionBiochemical and Biophysical Research Communications, 2023
- PROTAC technology: A new drug design for chemical biology with many challenges in drug discoveryDrug Discovery Today, 2022
- De Novo Design of an Androgen Receptor DNA Binding Domain‐Targeted peptide PROTAC for Prostate Cancer TherapyAdvanced Science, 2022
- Kill Two Birds with One Stone: A Multifunctional Dual‐Targeting Protein Drug to Overcome Imatinib Resistance in Philadelphia Chromosome‐Positive LeukemiaAdvanced Science, 2022
- Self-assembled hyaluronic acid nanoparticles for osteoarthritis treatmentBiomaterials, 2021
- Discovery of A031 as effective proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader for the treatment of prostate cancerEuropean Journal of Medicinal Chemistry, 2021
- Performance of ZDOCK and IRAD in CAPRI rounds 39‐45Proteins: Structure, Function, and Bioinformatics, 2020
- Targeted protein degradation: elements of PROTAC designCurrent Opinion in Chemical Biology, 2019
- Biodegradable Gelatin Methacryloyl Microneedles for Transdermal Drug DeliveryAdvanced Healthcare Materials, 2018